No Data
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.
Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.
Alfressa HD, MonotaRO, etc. (additional) Rating
Downgrade - Bearish Code Stock Name Securities Company Previous Change After ------------------------------------------------------------ <3659> Nexon Macquarie "Outperform" "Neutral" <6273> SMC Macquarie "Outperform" "Neutral" <6841> Yokogawa Electric Daiwa "2" "3" Target Price Change Code Stock Name Securities Company Previous Change After --------------------
The weekend's adjustments in positions have also resulted in active selection based on earnings reports.
The Nikkei average fell for the first time in four trading days. It closed at 39,149.43 yen, down 312.04 yen (with an estimated Volume of 2 billion 30 million shares). Profit-taking Sell orders were prioritized due to the backlash from consecutive days of rising stock prices. Although there were moments when it briefly turned positive at 39,543.93 yen, the yen exchange rate temporarily settled at around 152 yen to the dollar, which also led to profit-taking. Additionally, since the US market will be closed on the 17th, it seems there were movements for adjusting positions as well. The Nikkei average is expected to be followed.
In the fiscal year ending December 2024, VIS will promote mRNA-targeted small molecule drug discovery business and the creation of its own pipeline.
Veritas In Silico <130A> announced its fiscal results for the year ending December 2024 on the 13th. Business revenue decreased by 46.0% compared to the previous year to 0.194 billion yen, with an operating loss of 0.212 billion yen (compared to a profit of 0.037 billion yen in the previous term), an ordinary loss of 0.233 billion yen (compared to a profit of 0.035 billion yen in the previous term), and a net loss of 0.236 billion yen (compared to a profit of 0.033 billion yen in the previous term). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform ibVIS(R) is being utilized, and TORAY INDS INC <3402>.
Haseko, Daiwa House, ETC (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <8056> BIPROGY City "3" "2" Downgraded - Bearish Code Stock Name Brokerage Firm Previous Change After -------------------------------------------------------- <3659> Nexon Nomura "Buy" "